BSE Live
Nov 07, 16:01Prev. Close
1205.05
Open Price
1209.45
Bid Price (Qty.)
1205.30 (22)
Offer Price (Qty.)
1207.40 (43)
NSE Live
Nov 07, 15:58Prev. Close
1205.20
Open Price
1208.00
Bid Price (Qty.)
1205.40 (1249)
Offer Price (Qty.)
0.00 (0)
| Cash Flow of Dr Reddys Laboratories (in Rs. Cr.) | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 | |
| 12 mths | 12 mths | 12 mths | 12 mths | 12 mths | ||
| Net Profit/Loss Before Extraordinary Items And Tax | 7,235.90 | 5,791.30 | 3,866.00 | 2,223.80 | 3,056.20 | |
| Net CashFlow From Operating Activities | 4,225.00 | 3,449.70 | 5,052.90 | 1,338.70 | 3,514.20 | |
| Net Cash Used In Investing Activities | -5,697.60 | -3,430.30 | -3,447.60 | -2,038.00 | -1,458.00 | |
| Net Cash Used From Financing Activities | 1,590.70 | 68.10 | -2,696.90 | 505.50 | -794.30 | |
| Foreign Exchange Gains / Losses | 0.20 | 1.60 | 44.50 | 47.90 | 4.40 | |
| Adjustments On Amalgamation Merger Demerger Others | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Inc/Dec In Cash And Cash Equivalents | 118.30 | 89.10 | -1,047.10 | -145.90 | 1,266.30 | |
| Cash And Cash Equivalents Begin of Year | 201.40 | 112.30 | 1,159.40 | 1,305.40 | 39.10 | |
| Cash And Cash Equivalents End Of Year | 319.70 | 201.40 | 112.30 | 1,159.50 | 1,305.40 |
28.10.2025
Dr Reddys Labs Consolidated September 2025 Net Sales at Rs 8,828.30 crore, up 9.83% Y-o-Y
28.10.2025
Dr Reddys Labs Standalone September 2025 Net Sales at Rs 4,618.60 crore, down 31.03% Y-o-Y
24.10.2025
Dr Reddy's Q2 Results: Net profit rises 7% to Rs 1,347 crore, misses estimates
24.07.2025
Dr Reddys Labs Standalone June 2025 Net Sales at Rs 7,809.50 crore, up 33.7% Y-o-Y
22.01.2025
Dr Reddy's Labs Q3 Preview: Lower Revlimid contribution, subdued US sales to dent earnings growth
12.07.2023
Dr Reddys Laboratories Q1 PAT seen up 73.7% YoY to Rs 912.4 cr: Nirmal Bang
24.01.2023
Dr Reddy’s Q3 Preview | Sharp drop in net profit likely on slump in US revenues
27.10.2022
Dr Reddy’s Q2 preview: Pharma major likely to report sharp drop in net profit on weak US biz